Patent Covers Acclaim-3 Clinical Trials Combining REQORSA Gene Therapy with Genentech, Inc.’s Tecentriq® AUSTIN, Texas — (June 22, 2026) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ:...
The BIO International Convention Brings Together More Than 20,000 Biotech Industry Leaders From Around The World AUSTIN, Texas — (June 17, 2026) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ:...
Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine AUSTIN, Texas — (May 26, 2026) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ:...
Pdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four Weeks AUSTIN, Texas — (May 14, 2026) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators...
Strengthens Patent Estate and Expands Protection in Another Target Market AUSTIN, Texas — (April 30, 2026) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that The Israel Patent Office (ILPO) has granted...
Pdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four Weeks AUSTIN, Texas — (April 28, 2026) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators...
AUSTIN, Texas — (April 22, 2026) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators’ abstract has been selected for publication at the upcoming 2026 American Society of Clinical...
Research on Biomarkers May Help Enrich Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials, Potentially Predicting Patient Response to REQORSA Treatment Demonstrates Commitment to Tailored Treatment Options for Patients With Unmet Medical Need AUSTIN, Texas — (April 21, 2026) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ:...
TROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa® Gene Therapy REQORSA Induced Apoptosis and Decreased Tumor Volume in ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer Cell Lines and In Vivo Mouse Studies REQORSA Boosts Natural Killer (NK) Cell Antitumor Activity AUSTIN, Texas — (April 20, 2026) — Genprex, Inc....
Research Collaborators Identify Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy REQORSA is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer REQORSA Boosts Natural Killer (NK) Cell Antitumor Activity AUSTIN, Texas — (March 18, 2026) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ:...
AUSTIN, Texas — (March 10, 2026) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that members from its executive leadership team will be attending and participating at BIO Europe Spring taking place March...
Japanese Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.’s Tecentriq® AUSTIN, Texas — (Feb. 23, 2026) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ:...
Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.’s Tecentriq® Company Adds Additional Acclaim-3 Clinical Trial Site AUSTIN, Texas — (Feb. 10, 2026) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ:...